
To study the safety and efficacy of vitamin D3 as an add on therapy to zzso zzso zzso in patients with multiple sclerosis zzso 

1 year, double blind, zzso controlled, zzso study in 66 zzso zzso The primary outcomes were zzso burden of disease zzso on zzso scans, proportion of patients with serum levels of zzso D zzso zzso zzso or intact zzso hormone zzso zzso zzso and number of adverse zzso Secondary outcomes were number of zzso enhancing zzso zzso and new zzso zzso annual zzso rate, changes in the Expanded zzso zzso zzso score, timed 25 foot walk test and timed 10 foot tandem walk zzso 

Median change in zzso was zzso zzso in the zzso group and 83 zzso in the vitamin D group zzso zzso levels of zzso increased from a mean of 54 zzso zzso zzso to 110 zzso zzso zzso in the vitamin D zzso zzso of patients reached a serum zzso level zzso zzso in the vitamin D group and zzso in the zzso group zzso Patients in the vitamin D group showed fewer new zzso zzso zzso and a significantly lower number of zzso enhancing zzso zzso as well as a tendency to reduced disability zzso zzso and to improved timed tandem walk zzso There were no significant differences in adverse events or in the annual zzso zzso 

Vitamin D3 add on treatment to zzso reduces zzso disease activity in zzso 

zzso number zzso and zzso number zzso 

